Adaptimmune Therapeutics plc (NASDAQ:ADAP) CEO Adrian Rawcliffe sold 2,707 shares of the business’s stock in a transaction dated Tuesday, January 12th. The shares were sold at an average price of $6.15, for a total value of $16,648.05. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Adrian Rawcliffe also recently made the following trade(s):

  • On Monday, January 4th, Adrian Rawcliffe sold 4,967 shares of Adaptimmune Therapeutics stock. The shares were sold at an average price of $5.33, for a total value of $26,474.11.

NASDAQ ADAP opened at $5.82 on Thursday. The firm has a market cap of $757.23 million, a price-to-earnings ratio of -5.88 and a beta of 2.40. The business has a 50-day moving average price of $5.02 and a 200-day moving average price of $7.03. Adaptimmune Therapeutics plc has a twelve month low of $2.00 and a twelve month high of $13.40.

Adaptimmune Therapeutics (NASDAQ:ADAP) last posted its earnings results on Tuesday, November 10th. The biotechnology company reported ($0.24) EPS for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.01. The company had revenue of $1.19 million for the quarter, compared to the consensus estimate of $1.20 million. Adaptimmune Therapeutics had a negative return on equity of 44.94% and a negative net margin of 3,858.14%. On average, sell-side analysts forecast that Adaptimmune Therapeutics plc will post -0.9 earnings per share for the current fiscal year.

Several analysts have issued reports on ADAP shares. BidaskClub raised Adaptimmune Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, December 25th. SVB Leerink cut their price target on Adaptimmune Therapeutics from $10.00 to $6.00 and set a “market perform” rating for the company in a report on Thursday, November 5th. ValuEngine lowered Adaptimmune Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, October 19th. Finally, Zacks Investment Research lowered Adaptimmune Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, January 5th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and two have assigned a buy rating to the company’s stock. Adaptimmune Therapeutics has an average rating of “Hold” and an average price target of $14.25.

Several large investors have recently bought and sold shares of the stock. Victory Capital Management Inc. lifted its position in shares of Adaptimmune Therapeutics by 52.5% in the third quarter. Victory Capital Management Inc. now owns 2,922,819 shares of the biotechnology company’s stock worth $23,324,000 after buying an additional 1,006,439 shares in the last quarter. FMR LLC lifted its position in shares of Adaptimmune Therapeutics by 59.9% in the second quarter. FMR LLC now owns 2,523,783 shares of the biotechnology company’s stock worth $25,263,000 after buying an additional 945,000 shares in the last quarter. PFM Health Sciences LP purchased a new stake in shares of Adaptimmune Therapeutics in the third quarter worth about $6,779,000. JPMorgan Chase & Co. lifted its position in shares of Adaptimmune Therapeutics by 56.0% in the third quarter. JPMorgan Chase & Co. now owns 468,313 shares of the biotechnology company’s stock worth $3,587,000 after buying an additional 168,082 shares in the last quarter. Finally, Goldman Sachs Group Inc. purchased a new stake in shares of Adaptimmune Therapeutics in the second quarter worth about $4,391,000. Institutional investors own 99.79% of the company’s stock.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets.

Featured Article: Channel Trading

Insider Buying and Selling by Quarter for Adaptimmune Therapeutics (NASDAQ:ADAP)

Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.